Results 231 to 240 of about 103,481 (331)

Exploring Autophagy Inducing Molecules: Targeting Diverse Pathways in Alzheimer's Disease Management

Medicinal Research Reviews, EarlyView.
ABSTRACT Neurodegenerative disorders, including Alzheimer's disease (AD), impose a significant burden on society due to their progressive nature and the associated healthcare costs. Autophagy, a vital cellular degradation process, has emerged as a promising therapeutic target in these disorders.
Baljinder Singh, Shubham Mahajan, Sadikalmahdi Abdella, Rehan Khan, Sanjay Garg   +4 more
wiley   +1 more source

Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease. [PDF]

Brain Sci
Crispo JAG, Farhat N, Fortin Y, Perez-Lloret S, Sikora L, Morgan RL, Habash M, Gogna P, Kelly SE, Elliott J, Kohen DE, Bjerre LM, Mattison DR, Hessian RC, Willis AW, Krewski D.   +15 more
europepmc   +1 more source

A rationale for dopamine agonists as primary therapy for Parkinson's disease.

, 1992
C. Warren Olanow
openalex  

In Vivo Evidence that 5-HT2C Receptor Antagonist but not Agonist Modulates Cocaine-Induced Dopamine Outflow in the Rat Nucleus Accumbens and Striatum [PDF]

, 2003
Sylvia Navailles, Philippe De Deurwaerdère, Grégory Porras, Umberto Spampinato   +3 more
openalex   +1 more source

Light‐Based Molecular Tools to Precisely Monitor and Operate β‐Adrenoceptors

Medicinal Research Reviews, EarlyView.
ABSTRACT β‐Adrenoceptors are important G protein–coupled receptors involved in cardiovascular, metabolic, and neurological regulation. To study their function with high precision, light‐based molecular tools have been developed offering precise spatiotemporal control.
Ignazzitto Maria Tindara, Gómez‐Santacana Xavier, Llebaria Amadeu, Rovira Xavier   +3 more
wiley   +1 more source

Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown

Obesity, EarlyView.
ABSTRACT Objective Obesity affects 42% of older adults, with rates continuing to rise. This a complex condition influenced by non‐modifiable as well as modifiable risk factors. The disease can be treated through modifications to diet, physical activity, and behavior and more recently through antiobesity medications (AOMs) and surgery. Treatment must be
Anna Pendrey, Javier Sevilla‐Martir
wiley   +1 more source

Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center. [PDF]

Pituitary
Prencipe N, Bona C, Cuboni D, Berton AM, Bioletto F, Varaldo E, Aversa LS, Sibilla M, Gasco V, Ghigo E, Grottoli S.   +10 more
europepmc   +1 more source

Circadian Phase-Dependent Modulation of cGMP-Gated Channels of Cone Photoreceptors by Dopamine and D2 Agonist [PDF]

, 2003
Gladys Y.‐P. Ko, Michael L. Ko, Stuart E. Dryer   +2 more
openalex   +1 more source

Advances in Molecularly Imprinted Polymers for Bone Biomarker Detection and Therapeutic Applications

ChemistryOpen, EarlyView.
This review highlights the emerging applications of molecularly imprinted polymers (MIPs) in bone regeneration and diagnosis. MIPs facilitate osteogenic treatments by guiding stem cell differentiation and delivering bioactive molecules and enable precise detection of bone turnover biomarkers via MIP‐based sensors, offering promising strategies for next‐
Ren Yang, Xiaohan Ma, Mingcheng Xuan, Yingqi Ma, Jiexian Ding, David Y. S. Chau, Jonathan C. Knowles, Feng Peng, Alessandro Poma   +8 more
wiley   +1 more source

Treatment of social phobia with the dopamine agonist pergolide

, 2000
Gerardo Villarreal, Mike Johnson, Robert N. Rubey, R. Bruce Lydiard, James C. Ballanger   +4 more
openalex   +1 more source